European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention by Sacco, Simona et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
European headache federation guideline on the use of monoclonal antibodies acting
on the calcitonin gene related peptide or its receptor for migraine prevention
Sacco, Simona; Bendtsen, Lars; Ashina, Messoud; Reuter, Uwe; Terwindt, Gisela;
Mitsikostas, Dimos-Dimitrios; Martelletti, Paolo
Published in:
The Journal of Headache and Pain
DOI:
10.1186/s10194-018-0955-y
Publication date:
2019
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Sacco, S., Bendtsen, L., Ashina, M., Reuter, U., Terwindt, G., Mitsikostas, D-D., & Martelletti, P. (2019).
European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene
related peptide or its receptor for migraine prevention. The Journal of Headache and Pain, 20, [6].
https://doi.org/10.1186/s10194-018-0955-y
Download date: 03. Feb. 2020
CONSENSUS ARTICLE Open Access
European headache federation guideline
on the use of monoclonal antibodies acting
on the calcitonin gene related peptide or
its receptor for migraine prevention
Simona Sacco1* , Lars Bendtsen2, Messoud Ashina2, Uwe Reuter3, Gisela Terwindt4,
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Abstract
Background and aim: Monoclonal antibodies acting on the calcitonin gene-related peptide or on its receptor are
new drugs to prevent migraine. Four monoclonal antibodies have been developed: one targeting the calcitonin
gene-related peptide receptor (erenumab) and three targeting the calcitonin gene-related peptide (eptinezumab,
fremanezumab, and galcanezumab). The aim of this document by the European Headache Federation (EHF) is to
provide an evidence-based and expert-based guideline on the use of the monoclonal antibodies acting on the
calcitonin gene-related peptide for migraine prevention.
Methods: The guideline was developed following the Grading of Recommendation, Assessment, Development,
and Evaluation (GRADE) approach. The working group identified relevant questions, performed systematic review
and analysis of the literature, assessed the quality of available evidence, and wrote recommendations. Where the
GRADE approach was not applicable, expert opinion was provided.
Results: We found low to high quality of evidence to recommend eptinezumab, erenumab, fremanezumab, and
galcanezumab in patients with episodic migraine and medium to high quality of evidence to recommend erenumab,
fremanezumab, and galcanezumab in patients with chronic migraine. For several clinical questions, there was not
enough evidence to provide recommendations using the GRADE approach and recommendations relied on experts’
opinion.
Conclusion: Monoclonal antibodies acting on the calcitonin gene-related peptide are new drugs which can be
recommended for migraine prevention. Real life data will be useful to improve the use of those drugs in clinical
practice.
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Calcitonin gene-related peptide
* Correspondence: simona.sacco@univaq.it
†Dimos-Dimitrios Mitsikostas and Paolo Martelletti contributed equally to this
work.
1Neuroscience Section, Department of Applied Clinical Sciences and
Biotechnology, University of L’Aquila, via Vetoio, 67100 L’Aquila, Italy
Full list of author information is available at the end of the article
The Journal of Headache
                           and Pain
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made.
Sacco et al. The Journal of Headache and Pain            (2019) 20:6 
https://doi.org/10.1186/s10194-018-0955-y
Introduction
Migraine is a very common headache disorder affecting
around 15% of adult subjects [1–3]. It is ranked as the
second most disabling disease amongst all diseases glo-
bally [1]. Migraine may be associated with significant
morbidity and considerable negative impact on quality
of life [4]. Some patients may treat their migraine attacks
with drugs to relieve pain but in some patients because
of frequency, severity and impact on quality of life, pre-
ventive treatment is required to reduce the occurrence
of acute attacks and the need of medications to relieve
the pain.
Many years have passed since the first mechanism-based
drug, methysergide, was introduced for migraine treatment
[5]. Over the course of years, the use of this drug was dis-
missed because of safety profile. Other drugs, including
calcium-channel antagonists, antidepressants, antiepileptics,
anti-hypertensives developed for indications other than mi-
graine entered the field based on clinical studies [6–9].
However, efficacy is often insufficient and there is a latency
between initiation of the drug and clinical effect. Poor toler-
ability and side effects are important limitations of available
preventive treatments. Additionally, migraineurs seem to be
more sensitive to side-effects than patients suffering from
other diseases [10]. Those factors are the main reasons for
medication discontinuation and poor adherence which is
very often observed with available treatments [11–13]. Ad-
herence to treatment is only 20% after one year [14]. Add-
itionally, comorbidities limit the possibility of using
prophylactic drugs in some patients.
We have now four monoclonal antibodies (mAbs)
available acting on the calcitonin gene-related peptide
(CGRP) pathway which can be used for migraine pre-
vention: one targeting the CGRP receptor (erenumab)
and three targeting the CGRP peptide (eptinezumab, fre-
manezumab, and galcanezumab) [15–17]. Those new
treatments are migraine specific whereas all the other
available preventive drugs were developed for indications
other than migraine and have an unclear mechanism of
action considering migraine pathophysiology. Further-
more, CGRP mAbs seem to have very favorable
side-effects profile.
The European Headache Federation (EHF) initiated
this project to provide clinical guidance on the use of
the CGRP mAbs. The aim of this guideline is to provide
evidence-based and expert-based guidance to clinicians
for the management of episodic migraine (EM) and
chronic migraine (CM) with CGRP mAbs.
Methods
The EHF identified an expert Panel consisting of seven
members; all members are physicians. The Guideline was
developed according to the Grading of Recommendations,
Assessment, Development and Evaluation (GRADE) system
[18] as the method of choice to establish recommendations.
Members of the Panel group developed clinical questions
which were considered important for the management of
patients with EM or CM with CGRP mAbs. Clinical ques-
tions were developed, where possible, according to the
GRADE system as Patients; Intervention; Comparison and
Outcome (PICO) questions [18]. For PICO questions, state-
ments were developed according to the GRADE approach.
Outcomes rated as important or critical by members of the
group were considered. For questions where the GRADE
approach was not applicable recommendations were devel-
oped as expert statements.
Review of the literature
The search strategy was formulated taking into account
the PICO and clinical questions. A systematic review of
the literature was performed according to the Preferred
Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines [19]. We identified
key papers on the use CGRP mAbs in patients with mi-
graine. An initial literature search included all papers
indexed on PubMed and Scopus, from inception to April
2, 2018. The systematic literature search was repeated at
the end of the consensus procedure to include all rele-
vant papers published until November 2018. The follow-
ing search string was used in both databases: “migraine
OR headache AND (CGRP OR eptinezumab OR erenu-
mab OR fremanezumab OR galcanezumab)”. Two inves-
tigators independently screened the titles and abstracts
of the publications identified to verify study eligibility.
Literature screening was conducted in two steps. In the
first step, studies were excluded after reading the title
and the abstract for clear exclusion criteria. For studies
that passed the first step, the full text was assessed to
decide about inclusion/exclusion. Disagreements were
resolved by consensus. The reference lists and Google
Scholar citations of the selected articles were also
screened. The reasons for exclusion were recorded and
summarized. To summarize the search results, a data ex-
traction sheet was developed including the information
of interest. Papers retrieved from the literature search as
well as summary tables were shared among the
panelists.
Data extraction
A general description of the study was extracted for each
publication. We extracted first author name and year of
publication, full citation, study design and setting, study
period, number of included patients, diagnostic criteria
for migraine, migraine type, treatment type, duration of
observations and treatments, study results. Data extrac-
tion was performed by a single researcher (SS) and
double checked.
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Inclusion and exclusion criteria
Inclusion and exclusion criteria were selected prior to
the literature search.
We included 1) observational (prospective) and inter-
vention studies in which an CGRP mAb was assessed as
possible treatment strategy for migraine prevention; 2)
studies published in English or in other languages if a re-
liable translation could be obtained; 3) reliable criteria to
diagnose migraine; 4) treatment for migraine prevention
with any form of CGRP mAb; 5) reporting any outcome
referring to migraine frequency, severity, duration, dis-
ability, or use of drugs to treat the acute attacks before
and after treatment or in treated and untreated patients.
Whenever different studies referring to the same popula-
tion of patients were available we included the study
reporting the outcome of interest for the specific ana-
lysis or with the largest population or with the longest
follow-up; different studies can be eligible for different
questions. We excluded studies 1) with observational de-
signs not reporting outcomes with treatment or not
comparing at least two treatment strategies; 2) per-
formed in patients with headache other than migraine;
3) not reporting information on the outcomes selected
for the PICO and clinical questions; 4) published only in
the form of abstracts or presented at conferences only.
Quality assessment and analysis of evidence
For each of the selected studies one author (SS) ad-
dressed the quality of evidence. Quality of evidence was
addressed for single studies and for selected outcomes
according to the GRADE approach [18]. Randomized
trials were considered as high quality of evidence but
their quality was downgraded in the case of study limita-
tions such as lack of allocation concealment, lack of
blinding, incomplete accounting for patients and out-
come events, selective outcome reporting bias, or other
limitations such as inadequate sample or lack of sample
size calculation [20]. Observational studies were consid-
ered as low quality of evidence but their quality was
upgraded in the case of large magnitude effects,
dose-response gradient, if plausible confounding can in-
crease confidence in the estimate or other considerations
[21]. Final quality of evidence was rated as high,
medium, low or very low based on study design, study
limitations, inconsistency, indirectness, imprecision,
publication bias, effect size, dose response and con-
founding [18]. Summary of findings tables were drafted
using the GRADE pro statistical software considering all
the outcomes considered important or critical. For the
analysis of extracted data we used R statistical software.
Data analysis was performed on a random-effects basis
and results were summarized as risk ratio (RR) and 95%
confidence intervals (CI).
Development of the expert consensus
The consensus process was performed according to the
Delphi method [22]. Development of the consensus
statement was organized into rounds. In each round,
panelists were instructed not to discuss among them-
selves and to send their feedback only to the facilitator
(SS). The facilitator collected all the answers and issued
for each round an anonymized report with comments.
Rounds were repeated until a final consensus was
reached among Panel members.
Drafting of the statements
Strength (strong or weak) and direction (for or against)
of recommendation were determined on basis of balance
between desirable and undesirable effects, quality of evi-
dence, values and preferences and costs [18]. If GRADE
was not applicable, an ungraded good practice statement
based on experts’ opinions was given, according to the
available level of evidence.
Results
We identified 28 studies eligible to be considered in the
present guidelines (Fig. 1) [23–50]. Fourteen of the se-
lected studies (Tables 1 and 2) were phase II or III ran-
domized clinical trials (RCTs) reporting data on safety or
efficacy of the CGRP mAbs [26, 27, 31–36, 41–45, 50];
14 additional studies were post-hoc or pooled analyses
from the RCTs, open label-extension of the RCTs, or
open label studies [23–25, 28–30, 37–40, 46–49]. Risk of
bias summary for the selected studies is reported in
Fig. 2. Certainty assessment of outcomes for studies in
EM and CM is reported in Tables 3 and 4. Recommen-
dations related to the use of CGRP mAbs for prevention
of EM and CM are reported in Table 5.
PICO question 1 In patients with EM, is preventive
treatment with CGRP mAbs as compared to placebo, ef-
fective and safe?
Population: patients with EM.
Intervention: any preventive CGRP mAb.
Comparison: placebo.
Outcome: reduction in days of migraine or headache,
reduction in the use of acute attack medication, im-
provement in function, responder ratio (patients with >
50% reduction in migraine or headache days), serious
adverse events (SAEs), mortality (grade of importance:
critical).
Analysis of evidence
We found 14 eligible studies which evaluated whether treat-
ment with CGRP mAbs as compared to placebo is effective
and safe [26, 27, 31–36, 41–45, 50]. Among the eligible stud-
ies one was on eptinezumab [32], five studies on erenumab
[35, 36, 44, 45, 50], four studies on fremanezumab [26, 27,
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34, 41], and four studies on galcanezumab [31, 33, 42, 43].
One study phase IIIb study on erenumab was not included
in the PICO question 1 because it included only patients
with previous drug failure [50].
Eptinezumab
Summary of findings for treatment with eptinezumab
quarterly injection compared with placebo for preven-
tion of EM is provided in Table 6.
A phase II exploratory RCT evaluated the safety and
the efficacy of eptinezumab in subjects aged 18–55 years
with EM and attack frequency between 5 and 14 days
per month [32]. Patients were randomized to a single
intravenous injection of eptinezumab 1000mg or pla-
cebo. At weeks 9–12, there was no reduction in mi-
graine days in the eptinezumab compared to the placebo
group (mean difference [MD] -1.0; 95% confidence inter-
val [CI] -2.1 to + 0.2). There was a reduction of
migraines with acute migraine treatment in the eptine-
zumab compared to the placebo group (MD -10.4%; 95%
CI -20.5 to − 0.2). There was a non-significant improve-
ment in the Headache Impact Test 6 (HIT-6) score in
the eptinezumab group compared to the placebo group
(MD -2.4; 95% CI -5.5 to 0.7). The at least 50% re-
sponder rate was similar in the eptinezumab and in the
placebo group (MD 10%; 95% CI -4 to 24%). In the trial,
there were 6 SAEs (1 in the placebo group and 5 SAEs
in two patients in the erenumab group); the rate of SAEs
was 2.4% in the eptinezumab and 1.2% in the placebo
group. All the events were deemed to be unrelated to
eptinezumab. No deaths were reported.
Erenumab
Summary of findings for treatment with erenumab 70mg
monthly injection compared with placebo for prevention
Fig. 1 Process of identifying eligible studies for the guideline
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of EM is provided in Table 7 and with erenumab 140mg
monthly injection in Table 8.
A phase II RCT evaluated the safety and the efficacy
of erenumab in subjects aged 18–60 years with EM and
attack frequency between 4 and 14 days per month [44].
Patients were randomized to monthly subcutaneous in-
jections of erenumab 70mg or placebo for 3 months. At
3 month, there was a reduction in monthly migraine
days in the erenumab 70mg compared to placebo group
(least squares mean difference [LSMD] –1.1 days; 95%
CI –2.1 to − 0.2; P = 0.021). There was a reduction in the
number of days using acute medication in the erenumab
70mg compared to the placebo group (LSMD –1.2; 95%
CI –2.0 to − 0.3; P = 0.006). The at least 50% responder
Fig. 2 Risk of bias summary for the studies considered for the guideline
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rate was greater in the erenumab 70 mg group compared
to the placebo group (46% versus 30%; odds ratio [OR]
2.0; 95% CI 1.2 to 3.4; P = 0.011). In the trial, there were
2 SAEs; the rate of SAEs was 0.9% in erenumab 7mg
and 0.9% in erenumab 70mg group. All the events were
deemed to be unrelated to erenumab. No deaths were
reported.
A phase III RCT, the STRIVE, evaluated the efficacy of
erenumab in subjects aged 18–65 years with EM and at-
tack frequency between 4 and 14 days per month [36].
Patients were randomized to monthly subcutaneous in-
jections of erenumab 70mg, erenumab 140 mg or pla-
cebo for 6 months. At 4–6months, there was a
reduction in monthly migraine days in the erenumab 70
Table 3 Certainty in the assessment of efficacy outcomes for anti-calcitonin gene-related peptide monoclonal antibodies for
prevention in episodic migraine
Certainty assessment Certainty
Number of
studies
Study
design
Risk of
bias
Inconsistency Indirectness Imprecision Other
considerations
Eptinezumab
1000mg quarterly ev 1 RCT not
serious
seriousa not serious seriousb none ⨁⨁◯◯ LOW
Erenumab
70 monthly sc
(except functional improvement)
3 RCT not
serious
not serious not serious not serious none ⨁⨁⨁⨁ HIGH
70 monthly sc
(functional improvement)
1 RCT not
serious
seriousa not serious not serious none ⨁⨁⨁◯
MEDIUM
140 monthly sc 1 RCT not
serious
seriousa not serious not serious none ⨁⨁⨁◯
MEDIUM
Fremanezumab
225 monthly sc 2 RCT not
serious
not serious not serious not serious none ⨁⨁⨁⨁ HIGH
675 quarterly sc 1 RCT not
serious
seriousa not serious not serious none ⨁⨁⨁◯
MEDIUM
Galcanezumab
240mg ld + 120mg monthly sc 1 RCT not
serious
seriousa not serious not serious none ⨁⨁⨁◯
MEDIUM
240mg monthly sc 1 RCT not
serious
seriousa not serious not serious none ⨁⨁⨁◯
MEDIUM
sc Subcutaneous, ev Endovenous, RCT Randomized controlled trial. aInconsistency because of lack of replication; bImprecision because of exploratory study
Table 4 Certainty in the assessment of efficacy outcomes for anti-calcitonin gene-related peptide monoclonal antibodies for
prevention in chronic migraine
Certainty assessment Certainty
Number of
studies
Study
design
Risk of
bias
Inconsistency Indirectness Imprecision Other
considerations
Erenumab
70 monthly sc 1 RCT not serious seriousa not serious not serious none ⨁⨁⨁◯ MEDIUM
140 monthly sc 1 RCT not serious seriousa not serious not serious none ⨁⨁⨁◯ MEDIUM
Fremanezumab
675 quarterly sc 1 RCT not serious seriousa not serious not serious none ⨁⨁⨁◯ MEDIUM
675 ld + 225 quarterly sc
(except functional improvement)
2 RCT not serious not serious not serious not serious none ⨁⨁⨁⨁ HIGH
675 ld + 225 quarterly sc
(functional improvement)
1 RCT not serious seriousa not serious not serious none ⨁⨁⨁◯ MEDIUM
Galcanezumab
240mg ld + 120mg monthly sc 1 RCT not serious seriousa not serious not serious none ⨁⨁⨁◯ MEDIUM
240mg monthly sc 1 RCT not serious seriousa not serious not serious none ⨁⨁⨁◯ MEDIUM
sc Subcutaneous, ld Loading dose, RCT Randomized controlled trial. aInconsistency because of lack of replication
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mg (LSMD -1.4; SE -1.9 to − 0.9) and in the erenumab
140 mg (LSMD -1.9; SE -2.3 to − 1.4) groups compared
to the placebo group. There was a reduction in the
monthly number of days using acute medications in the
erenumab 70mg (LSM -0.9; SE -1.2 to − 1.6) and in the
erenumab 140 mg (LSM -1.4; SE -1.7 to − 1.1) groups
compared to the placebo group. There was an improve-
ment in the monthly migraine Physical Function Impact
Diary (MPFID) everyday-activities score in the erenumab
70mg (LSMD -2.2; 95% CI -3.3 to − 1.2) and in the ere-
numab 140 mg (LSMD -2.6; 95% CI-3.6 to − 1.5) groups
compared to the placebo group. There was an improve-
ment in the monthly MPFID physical-impairment score
in the erenumab 70mg (LSMD -1.9; 95% CI -3.0 to −
0.8) and in the erenumab 140 mg (LSMD -2.4; 95% CI
-3.4 to − 1.4) groups compared to the placebo group.
The at least 50% responder rate was greater in the ere-
numab 70 mg (OR 2.13; 95% CI 1.52 to 2.98) and in the
erenumab 140 mg (OR 2.81; 95% CI 2.01 to 3.94) groups
compared to the placebo group. In this trial, there were
21 SAEs; the rate of SAEs was 2.5% in the erenumab 70
mg, 1.9% in the erenumab 140 mg, and 2.2% in the pla-
cebo group. SAEs were not related to study drug. No
deaths were reported.
A phase III RCT, the ARISE, evaluated the efficacy of
erenumab in subjects aged 18–65 years with EM and at-
tack frequency between 4 and 14 days per month [35].
Patients were randomized to monthly subcutaneous in-
jections of erenumab 70mg or placebo for 3 months. At
week 12, there was a significant reduction in the
monthly migraine days in the erenumab compared to
the placebo group (LSMD -1.0; 95% CI -1.6 to − 0.5; P <
0.001). There was a significant reduction in the number
of days using acute migraine-specific medication (trip-
tan/ergot) in the erenumab compared to the placebo
group (LSMD -0.6; SE -1.0 to − 0.2; P = 0.002). There
was a significant improvement in modified monthly
MIDAS total scores in the erenumab compared to the
placebo group (LSMD -1.7; SE -3.1 to − 0.3; P = 0.021).
The at least 50% responder rate per month was greater
in the erenumab compared to the placebo group (OR
1.59; 95% CI 1.12 to 2.27; P = 0.010). In this trial, there
were 8 SAEs; the rate of SAEs was 1.1% in the erenumab
70mg and 1.7% in the placebo group. No deaths were
reported.
Fremanezumab
Summary of findings for treatment with fremanezumab
225 mg monthly injection compared with placebo for
prevention of EM is provided in Table 9 and with frema-
nezumab 675 mg quarterly injection in Table 10.
A phase II RCT evaluated the safety and the efficacy
of fremanezumab in subjects aged 18–65 years with EM
and migraine day frequency between 8 and 14 days per
month [27]. Patients were randomized to subcutaneous
injections every 28 days of fremanezumab 225mg, fre-
manezumab 675 mg or placebo for three treatment cy-
cles. At week 9–12, there was a reduction in migraine
days in the fremanezumab 225 mg (LSMD -2.81; 95% CI
–4.07 to − 1.55; p < 0.0001) and in the fremanezumab
675 mg (LSMD –2.64; 95% CI–3.90 to − 1.38; P <
0.0001) groups compared to the placebo group. There
Table 5 Recommendations on the use of calcitonin gene-related peptide monoclonal antibodies for the prevention of episodic and
chronic migraine
Setting Drug Recommendation Quality of evidence Strength of the
recommendation
Migraine prevention in patients with episodic migraine
Eptinezumab 1000mg quarterly Suggested ⨁⨁◯◯ LOW ↑? Weak
Erenumab 70 mg monthly Recommended ⨁⨁⨁⨁ HIGH ↑↑ Strong
Erenumab 140mg monthly Recommended ⨁⨁⨁◯ MEDIUM ↑↑Strong
Fremanezumab 225mg monthly Recommended ⨁⨁⨁⨁ HIGH ↑↑ Strong
Fremanezumab 675mg quarterly Recommended ⨁⨁⨁◯ MEDIUM ↑↑Strong
Galcanezumab 240mg loading dose + 120mg monthly Recommended ⨁⨁⨁◯ MEDIUM ↑↑ Strong
Galcanezumab 240mg monthly Recommended ⨁⨁⨁◯ MEDIUM ↑↑ Strong
Migraine prevention in patients with chronic migraine
Erenumab 70 mg monthly Recommended ⨁⨁⨁◯ MEDIUM ↑↑Strong
Erenumab 140mg monthly Recommended ⨁⨁⨁◯ MEDIUM ↑↑Strong
Fremanezumab 675mg quarterly Recommended ⨁⨁⨁◯ MEDIUM ↑↑Strong
Fremanezumab 675mg loading dose + 225mg monthly Recommended ⨁⨁⨁⨁ HIGH ↑↑ Strong
Galcanezumab 240mg loading dose + 120mg monthly Recommended ⨁⨁⨁◯ MEDIUM ↑↑Strong
Galcanezumab 240mg monthly Recommended ⨁⨁⨁◯ MEDIUM ↑↑Strong
Symbols depict the strength of the recommendation according to the GRADE system
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was a reduction in the number of days with acute medi-
cations in the fremanezumab 225 mg (LSMD 1.76; 95 CI
-2.86 to − 0.66; P = 0.0018) and in the fremanezumab
675 mg (LSMD 1.70; 95 CI -2.80 to − 0.60; P = 0.0026)
groups compared to the placebo group. There was an
improvement in Migraine Disability Assessment
(MIDAS) scores in the fremanezumab 225 mg (LSMD
-14.50; 95% -26.79 to − 2.20; P = 0.021) and in the frema-
nezumab 675 mg (LSMD -15.20; 95% -27.62 to − 2.78; P
= 0.017) groups compared to the placebo group. The at
least 50% responder rate was 28% in the placebo group,
53% in the fremanezumab 225 mg group (P = 0.0005)
and 59% in the fremanezumab 675 mg group (P <
0.0001). In this trial, there were 4 SAEs; the rate of SAEs
was 2% in the fremanezumab 225 mg and 2% in the fre-
manezumab 675 mg group. All the events were deemed
to be unrelated to fremanezumab. No SAEs were re-
ported in the placebo group. No deaths were reported.
A phase III RCT, the HALO EM, evaluated the safety
and the efficacy of fremanezumab in subjects aged 18–
70 years with EM and attack frequency between 6 and
14 days per month [34]. Patients were randomized to
monthly subcutaneous injections of fremanezumab 225
mg, to quarterly fremanezumab 675 mg, or placebo for
3 months. At 3 months, there was a significant reduction
in monthly migraine days in the fremanezumab 225 mg
(LSMD –1.5; 95% CI –2.01 to − 0.93; P < 0.001) and in
the fremanezumab 675mg (LSMD –1.3; 95% CI –1.79
to − 0.72; P < 0.001) groups compared to the placebo
group. There was a significant reduction in the monthly
number of days using acute medication in the fremane-
zumab 225 mg (LSMD -1.4; 95% CI –1.84 to − 0.89; P
< .001) and in the fremanezumab 675 mg (LSMD –1.3;
95% CI –1.76 to − 0.82; P < 0.001) groups compared to
the placebo group. There was an improvement in mean
MIDAS scores in the fremanezumab 225 mg (LSMD –
7.0; 95% CI –10.51 to − 3.53; P < 0.001) and in the fre-
manezumab 675 mg (LSMD –5.4; 95% CI –8.90 to −
1.93; P = 0.002) groups compared to the placebo group.
The at least 50% responder rate was higher in the frema-
nezumab 225mg (difference vs placebo, 19.8%; 95% CI
12.0%–27.6%; P < 0.001) and in the fremanezumab 675
mg (difference vs placebo, 16.5%; 95% CI 8.9%–24.1%; P
< 0.001) groups compared to the placebo group. In this
trial there were 13 SAEs; the rate of SAEs was 1.0% in
the fremanezumab 225 mg, 1.0% in the fremanezumab
675 mg, and 2.4% in the placebo group. One death oc-
curred in the fremanezumab 675 mg group; the event
was considered unrelated to treatment.
Galcanezumab
Summary of findings for treatment with galcanezumab
120 mg monthly injection (240mg loading dose) com-
pared with placebo for prevention of EM is provided in
Table 11 and with galcanezumab 240 mg monthly injec-
tion in Table 12.
A phase II RCT evaluated the safety and the efficacy
of galcanezumab in subjects aged 18–65 years with EM
and attack frequency between 4 and 14 days per month
[33]. Patients were randomized to subcutaneous injec-
tions every two weeks of galcanezumab 150 mg or pla-
cebo for 3 months. No concomitant preventive
medication was allowed. At 9–12 week, there was a re-
duction in the number of migraine days in the galcane-
zumab compared to the placebo group (LSMD –1.2;
90% CI –1.9 to − 0.6). There were more at least 50% re-
sponder rate in the galcanezumab compared to the pla-
cebo group (OR 2.88, 90% CI 1.78–4.69). In this trial,
there were 6 SAEs; the rate of SAEs was 1.9% in the gal-
canezumab and 3.6% in the placebo group. The events
were considered unrelated to treatment. No deaths oc-
curred in the study.
A phase II RCT, the EVOLVE-2, evaluated the efficacy
of galcanezumab in subjects aged 18–65 years with EM
and attack frequency between 4 and 14 days per month
[42]. Patients were randomized to subcutaneous injec-
tion once a month of galcanezumab 5, 50, 120, or 300
mg or placebo for 3 months. No concomitant preventive
medication was allowed. At 9–12 week, there was a
greater improvement in migraine days in the galcanezu-
mab 120mg (− 4.8, 90% Bayesian credible interval [BCI],
− 5.4 to − 4.2) compared to the placebo group (− 3.7,
90% BCI, − 4.1 to − 3.2). There was a greater improve-
ment from baseline in the HIT-6 score in the galcanezu-
mab, 120 mg (LSMD − 10.0; 95% CI, − 12.2 to − 7.7; P =
0.04) compared to placebo group (LSMD − 7.3; 95% CI
− 8.8 to − 5.7). In this trial, there were 4 SAEs; the rate
of SAEs was 1.5% in the galcanezumab and 0 in the pla-
cebo group. The events were considered unrelated to
treatment. No deaths occurred in the study.
A phase III RCT, the EVOLVE-1, evaluated the safety
and the efficacy of galcanezumab in subjects aged 18–
65 years with EM and attack frequency between 4 and
14 days per month [43]. Patients were randomized to
monthly subcutaneous injections of galcanezumab 120
mg (with a loading dose of 240 mg), galcanezumab 240
mg or placebo for 6 months. At 1–6 month, there was a
reduction in monthly migraine days averaged over the
entire study period in the galcanezumab 120 mg (LSMD
-1.9; SE -2.5 to − 1.4; P < 0.001) and in the galcanezumab
240 mg (LSMD -1.8; SE -2.3 to − 1.3; P < 0.001) group
compared to placebo group. There was a reduction in
the monthly number of migraine days using acute medi-
cation in the galcanezumab 120 mg (LSMD -1.8; SE -2.3
to − 1.3; P < 0.001) and in the galcanezumab 240 mg
(LSMD -1.6; SE -2.1 to − 1.1; P < 0.001) group compared
to placebo group. There was an improvement in the
MIDAS total score in the galcanezumab 120mg (LSMD
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− 21.2; SE 1.7; P < 0.001) and in the galcanezumab 240
mg (LSMD − 20.1; SE 1.7; P < .002) groups compared to
placebo group. The at least 50% responder rate was
greater in galcanezumab 120 mg (OR 2.6; 95% CI 2.0–
3.4; P < 0.001) and in galcanezumab 240 mg (OR 2.5;
95% CI 1.9–3.2; P < 0.001) groups compared to placebo
group. In this trial, there were 12 SAEs in 11 patients;
the rate of SAEs was 2.9% in the galcanezumab 120 mg,
0 in the galcanezumab 240mg, and 1.2% in the placebo
group. The events were considered unrelated to treat-
ment. No deaths occurred in the study.
Clinical guidance
Available studies indicated that erenumab, fremanezu-
mab, and galcanezumab are effective for prevention in
patients with EM. They reduce the number of headache
or migraine days, reduce the number of days using acute
medications, improve disability. Evidence for erenumab,
fremanezumab, and galcanezumab is based on phase II
and III RCTs. For eptinezumab benefits are not entirely
clear and improvement was significant only in the reduc-
tion of medications used for acute attacks; additionally,
evidence is based on an exploratory phase II RCT. Epti-
nezumab is administered via intravenous injection while
erenumab, fremanezumab, and galcanezumab are ad-
ministered via subcutaneous injections. Ease of use rep-
resents a potential advantage as CGRP mAbs offer the
convenience and adherence benefits of monthly or quar-
terly dosing allowing avoidance of the daily pill burden.
Treatment effect was evident after the first injection and
patients continued to improve within the fifth month of
treatment [41–43]. The quick onset of action is a poten-
tial advantage of CGRP mAbs as compared to conven-
tional treatments. Reduction in migraine days with
CGRP mAbs were only modest and ranged from 1 to 2
when compared to placebo. However, the absolute effect
of treatment was larger considering also the placebo ef-
fect. Perhaps, more clinically significant is the at least
50% responder rate, which was consistently increased
with treatment in a clinically meaningful way. A propor-
tion of patients may have a 100% response rate to CGRP
mAbs [39]. The open-label extension of the phase II
RCT of erenumab reported low discontinuation rates
[24] which is in contrast to current migraine prophylac-
tics that are associated with high discontinuation rates
[8, 51, 52]. Post-hoc analyses of the RCTs indicated that
treatment with fremanezumab is associated with im-
proved normal function performance on headache free
days [46] and that treatment with galcanezumab is asso-
ciated with overall functional improvement [23]. At the
moment, it cannot be determined whether unique pa-
tient populations will have a response to a specific drug.
Data from RCTs indicated that the CGRP mAbs are
safe. No relevant SAEs were registered. One death
occurred in the phase III RCT on fremanezumab [34]
and one death occurred in the open label extension trial
on erenumab [24]. Both deaths were considered unre-
lated to the study drugs. However, it should be noted
that further data from the real-life setting are needed to
support safety and to provide information on the
long-term use.
PICO question 2 In patients with CM, is preventive
treatment with CGRP mAbs as compared to placebo, ef-
fective and safe?
Population: patients with CM.
Intervention: any CGRP mAb.
Comparison: placebo.
Outcome: reduction in days of migraine or headache,
reduction in the use of acute attack medication, im-
provement in function, responder ratio (patients with >
50% reduction in migraine or headache days), serious
adverse events, mortality (grade of importance: critical).
Analysis of evidence
We found four eligible studies which evaluated whether
treatment with CGRP mAbs as compared to placebo is
effective and safe [26, 31, 41, 45]. Among the eligible
studies one study was on erenumab [45], two studies on
fremanezumab [26, 41], and one on galcanezumab [31].
Erenumab
Summary of findings for treatment with erenumab 70
mg monthly injection compared with placebo for pre-
vention of CM is provided in Table 13 and with erenu-
mab 140 mg monthly injection in Table 14.
A phase II RCT evaluated the safety and the efficacy
of erenumab in subjects aged 18–65 years with CM [45].
Patients were randomized to monthly subcutaneous in-
jection of erenumab 70mg, erenumab 140 mg or placebo
for 3 months. At weeks 9–12, there was a reduction in
monthly migraine days in the erenumab 70 mg (LSMD
-2.5; SE -3.5 to − 1.4; P < 0.0001) and in the erenumab
140 mg (LSMD -2.5; SE -3.5 to − 1.4; P < 0.0001) groups
compared to placebo group. There was a reduction in
monthly number of days using migraines-specific medi-
cation in the erenumab 70mg (LSMD-1.9; SE -2.6 to −
1.1; P < 0.0001) and in the erenumab 140 mg (LSMD
-2.6; SE -3.3 to − 1.8; P < 0.0001) groups compared to
the placebo group. The at least 50% responder rate was
greater in the erenumab 70 mg (40% versus 23%; OR 2.2;
95% CI 1.5 to 3.3; P = 0.0001) and in the erenumab 140
mg (41% versus 23%; OR 2.3; 95% CI 1.6 to 3.5; P <
0.0001) groups compared to the placebo group. In this
trial, there were 15 SAEs; the rate of SAEs was 3% in
erenumab 70mg, 1% in erenumab 140 mg, and 2% in
the placebo group. No deaths were reported.
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Fremanezumab
Summary of findings for treatment with fremanezumab
675 mg quarterly injection compared with placebo for
prevention of CM is provided in Table 15 and with fre-
manezumab 225 mg monthly injection (675 loading
dose) in Table 16.
A phase II RCT evaluated the safety, the tolerability,
and the efficacy of fremanezumab in subjects aged 18–
65 years with CM [26]. Patients were randomized to
three 28-day treatment cycles of subcutaneous injections
of fremanezumab 225 mg (loading dose 675 mg), frema-
nezumab 900 mg or placebo. At weeks 9–12, there was a
reduction in moderate to severe headache days in the
fremanezumab 675/225 mg (LSMD -1.84; 95% CI -3.54
to − 0.14; P = 0.0345) and in the fremanezumab 900 mg
(LSMD -1.96; 95% CI -3.66 to − 0.26; P = 0.0237) groups
compared to placebo group. There was a reduction in
number of days using acute medication in the fremane-
zumab 900 mg (LSMD -2.04; 95% CI -3.9 to − 0.2; P =
0.027) group compared to placebo group. The at least
50% responder rate considering moderate to severe
headaches was greater in the fremanezumab 675/225 mg
(OR 2.44; 95% CI 1.3 to 4.5; P = 0.004) and in the frema-
nezumab 900 mg (OR 2.97; 95% CI 1.6 to 5.5; P = 0.013)
groups compared to placebo group. In this trial, there
were 4 SAEs; the rate of SAEs was 1% in the fremanezu-
mab 675/225 mg, 2% in the fremanezumab 900 mg, and
1% in the placebo group. All the events were deemed to
be unrelated to fremanezumab. No deaths were
reported.
A phase III RCT, the HALO CM, evaluated the effi-
cacy of fremanezumab in subjects aged 18–70 years with
CM [41]. Patients who had failed 2 of four clusters of
preventive treatments were excluded; migraine prevent-
ive drugs were permitted during the study in up to 30%
of included patients. Patients were randomized to
monthly subcutaneous injections of fremanezumab 225
mg (loading dose of 675 mg), to quarterly fremanezumab
675 mg, or placebo for 3 months. During 12-week
period, there was a reduction in the average number of
headache days per month in the fremanezumab 675 mg
(LSMD -1.8; SE 0.3; P < 0.001) and in the fremanezumab
675/225 mg (LSMD -2.1; SE 0.3; P < 0.001) groups com-
pared to placebo group. There was a reduction in the
monthly number of days using acute medication in the
fremanezumab 675mg (LSMD -1.8; SE 0.3; P < 0.001)
and in the fremanezumab 675/225 mg (LSMD -2.3; SE
0.3; P < 0.001) groups compared to placebo group. There
was an improvement in the HIT-6 score in the fremane-
zumab 675mg (LSMD -1.9; SE 0.5; P < 0.001) and in the
fremanezumab 675/225 mg (LSMD -2.4; SE 0.5; P <
0.001) groups compared to placebo group. The at least
50% responder rate was increased in the fremanezumab
675 mg (38%) and in the fremanezumab 675/225 mg
(41%) groups compared to placebo group (18%; P <
0001). In this trial, there were 14 SAEs; the rate of SAEs
was < 1% in the fremanezumab 675mg, 1% in the frema-
nezumab 675/225 mg, and 2% in the placebo group. One
SAE lead to discontinuation of the trial. One death oc-
curred in the fremanezumab 675 mg group and was
deemed to be unrelated to fremanezumab.
Galcanezumab
Summary of findings for treatment with galcanezumab
120 mg monthly injection (240mg loading dose) com-
pared with placebo for prevention of CM is provided in
Table 17 and with galcanezumab 240 mg monthly injec-
tion in Table 18.
A phase III RCT, the REGAIN, evaluated the efficacy
of galcanezumab in subjects aged 18–65 years with CM
[31]. Patients were randomized to monthly subcutaneous
injections of galcanezumab 120 mg (loading dose of 240
mg at baseline), galcanezumab 240 mg, or placebo for 3
months. During the 3-month period, there was a reduc-
tion in monthly migraine days in the galcanezumab 120
mg group (LSMD -2.1; 95% CI -2.9 to − 1.3) and with
galcanezumab 240 mg (LSMD -1.9; 95% CI -2.7 to − 1.1)
compared to placebo groups. There was a reduction in
monthly number of days using acute medication use in
the galcanezumab 240 mg (LSMD -2.0; 95% CI -2.8 to −
1.3) but not in galcanezumab 120mg as compared to
the placebo group. There was an improvement in the
MIDAS score in the galcanezumab 120 mg (LSMD -8.7;
95% CI -16.4 to − 3.1) but not in galcanezumab 240 mg
as compared to the placebo group. The at least 50% re-
sponder rate was increased in the galcanezumab 120 mg
(OR 2.1; 95% CI 1.6–2.8) and in the galcanezumab 240
mg (OR 2.1; 95% CI 1.6–2.8) groups compared to pla-
cebo group. In this trial, there were 10 SAEs; the rate of
SAE was 0.4% in the galcanezumab 120 mg, 1.8% in the
galcanezumab 240 mg, and 0.7% in the placebo group.
No deaths were reported.
Clinical guidance
Available studies indicate that erenumab, fremanezumab,
and galcanezumab are effective for prevention in pa-
tients with CM. They reduce the number of headache
days, reduce the number of days using acute medica-
tions, improve disability, and are safe. For erenumab evi-
dence is based on a phase II RCT which however was
not a dose finding exploratory study but a RCT to assess
safety and efficacy. For fremanezumab evidence is based
also on phase II and on a phase III RCT while for galca-
nezumab it is based on a phase III RCT. Studies in-
cluded patients with a long history of disease and those
who had previously failed two or more preventive medi-
cations. The trials did not include patients with more
Sacco et al. The Journal of Headache and Pain            (2019) 20:6 Page 21 of 33
Ta
b
le
15
Su
m
m
ar
y
of
fin
di
ng
s
ta
bl
e
fo
r
tr
ea
tm
en
t
w
ith
fre
m
an
ez
um
ab
67
5
m
g
qu
ar
te
rly
su
bc
ut
an
eo
us
in
je
ct
io
n
co
m
pa
re
d
w
ith
no
tr
ea
tm
en
t
fo
r
pr
ev
en
tio
n
of
ch
ro
ni
c
m
ig
ra
in
e
O
ut
co
m
es
A
nt
ic
ip
at
ed
ab
so
lu
te
ef
fe
ct
s
(9
5%
C
I)
Re
la
tiv
e
ef
fe
ct
(9
5%
C
I)
№
of
pa
rt
ic
ip
an
ts
(s
tu
di
es
)
C
er
ta
in
ty
of
th
e
ev
id
en
ce
(G
RA
D
E)
C
om
m
en
ts
Ri
sk
w
ith
pl
ac
eb
o
Ri
sk
w
ith
Fr
em
an
ez
um
ab
Re
du
ct
io
n
of
m
on
th
ly
he
ad
ac
he
da
ys
fo
llo
w
up
:3
m
on
th
s
Th
e
m
ea
n
re
du
ct
io
n
of
m
on
th
ly
he
ad
ac
he
da
ys
w
as
−
2.
5
da
ys
Th
e
m
ea
n
re
du
ct
io
n
of
m
on
th
ly
he
ad
ac
he
da
ys
in
th
e
in
te
rv
en
tio
n
gr
ou
p
w
as
1.
8
da
ys
fe
w
er
(2
.4
fe
w
er
to
1.
2
fe
w
er
)
–
74
6
(1
RC
T)
⨁
⨁
⨁
◯
M
ED
IU
M
a
Tr
ea
tm
en
t
w
ith
Fr
em
an
ez
um
ab
67
5
m
g
re
du
ce
s
m
on
th
ly
he
ad
ac
he
da
ys
sl
ig
ht
ly
co
m
pa
re
d
to
pl
ac
eb
o.
Re
du
ct
io
n
of
m
on
th
ly
ac
ut
e
tr
ea
tm
en
t
da
ys
fo
llo
w
up
:3
m
on
th
s
Th
e
m
ea
n
re
du
ct
io
n
of
m
on
th
ly
ac
ut
e
tr
ea
tm
en
t
da
ys
w
as
−
1.
9
da
ys
Th
e
m
ea
n
re
du
ct
io
n
of
m
on
th
ly
ac
ut
e
tr
ea
tm
en
t
da
ys
in
th
e
in
te
rv
en
tio
n
gr
ou
p
w
as
1.
8
da
ys
fe
w
er
(2
.4
fe
w
er
to
1.
2
fe
w
er
)
–
74
6
(1
RC
T)
⨁
⨁
⨁
◯
M
ED
IU
M
a
Tr
ea
tm
en
t
w
ith
Fr
em
an
ez
um
ab
67
5
m
g
re
du
ce
s
m
on
th
ly
ac
ut
e
tr
ea
tm
en
t
da
ys
sl
ig
ht
ly
co
m
pa
re
d
to
pl
ac
eb
o.
Im
pr
ov
em
en
t
in
fu
nc
tio
na
l
H
IT
-6
sc
or
e
fo
llo
w
up
:
3
m
on
th
s
Th
e
m
ea
n
im
pr
ov
em
en
t
in
fu
nc
tio
na
lH
IT
-6
sc
or
e
w
as
−
4.
5
po
in
ts
Th
e
m
ea
n
im
pr
ov
em
en
t
in
fu
nc
tio
na
l
H
IT
-6
sc
or
e
in
th
e
in
te
rv
en
tio
n
gr
ou
p
w
as
1.
9
po
in
ts
fe
w
er
(2
.9
fe
w
er
to
0.
9
fe
w
er
)
–
74
6
(1
RC
T)
⨁
⨁
⨁
◯
M
ED
IU
M
a
Tr
ea
tm
en
t
w
ith
fre
m
an
ez
um
ab
67
5
m
g
im
pr
ov
es
fu
nc
tio
na
lH
IT
-6
sc
or
e
sl
ig
ht
ly
co
m
pa
re
d
to
pl
ac
eb
o.
A
t
le
as
t
50
%
re
du
ct
io
n
of
m
on
th
ly
he
ad
ac
he
da
ys
fo
llo
w
up
:3
m
on
th
s
18
1
pe
r
10
00
37
6
pe
r
10
00
(2
92
to
48
4)
RR
2.
08
20
(1
.6
16
7
to
2.
68
13
)
74
6
(1
RC
T)
⨁
⨁
⨁
◯
M
ED
IU
M
a
Tr
ea
tm
en
t
w
ith
Fr
em
an
ez
um
ab
67
5
m
g
re
su
lts
in
at
le
as
t
50
%
re
du
ct
io
n
of
m
on
th
ly
he
ad
ac
he
da
ys
co
m
pa
re
d
to
pl
ac
eb
o.
Se
rio
us
ad
ve
rs
e
ev
en
ts
fo
llo
w
up
:3
m
on
th
s
16
pe
r
10
00
8
pe
r
10
00
(2
to
32
)
RR
0.
49
87
(0
.1
25
6
to
1.
97
92
)
75
1
(1
RC
T)
⨁
⨁
⨁
◯
M
ED
IU
M
a
Tr
ea
tm
en
t
w
ith
Fr
em
an
ez
um
ab
67
5
m
g
re
su
lts
in
an
un
im
po
rt
an
t
re
du
ct
io
n
of
se
rio
us
ad
ve
rs
e
ev
en
t
oc
cu
rr
en
ce
co
m
pa
re
d
to
pl
ac
eb
o.
M
or
ta
lit
y
fo
llo
w
up
:
3
m
on
th
s
0
pe
r
10
00
<
1
pe
r
10
00
RR
2.
99
20
(0
.1
22
3
to
73
.2
17
4)
75
1
(1
RC
T)
N
o
de
at
hs
w
er
e
ob
se
rv
ed
w
ith
tr
ea
tm
en
t
w
ith
Fr
em
an
ez
um
ab
67
5
m
g
or
pl
ac
eb
o
CI
C
on
fid
en
ce
in
te
rv
al
,R
R
Ri
sk
ra
tio
,R
CT
Ra
nd
om
iz
ed
co
nt
ro
lle
d
tr
ia
l;
a D
ow
ng
ra
de
d
on
ce
du
e
to
in
co
ns
is
te
nc
y
G
RA
D
E
W
or
ki
ng
G
ro
up
gr
ad
es
of
ev
id
en
ce
H
ig
h
ce
rt
ai
nt
y:
W
e
ar
e
ve
ry
co
nf
id
en
t
th
at
th
e
tr
ue
ef
fe
ct
lie
s
cl
os
e
to
th
at
of
th
e
es
tim
at
e
of
th
e
ef
fe
ct
M
od
er
at
e
ce
rt
ai
nt
y:
W
e
ar
e
m
od
er
at
el
y
co
nf
id
en
t
in
th
e
ef
fe
ct
es
tim
at
e:
Th
e
tr
ue
ef
fe
ct
is
lik
el
y
to
be
cl
os
e
to
th
e
es
tim
at
e
of
th
e
ef
fe
ct
,b
ut
th
er
e
is
a
po
ss
ib
ili
ty
th
at
it
is
su
bs
ta
nt
ia
lly
di
ff
er
en
t
Lo
w
ce
rt
ai
nt
y:
O
ur
co
nf
id
en
ce
in
th
e
ef
fe
ct
es
tim
at
e
is
lim
ite
d:
Th
e
tr
ue
ef
fe
ct
m
ay
be
su
bs
ta
nt
ia
lly
di
ff
er
en
t
fr
om
th
e
es
tim
at
e
of
th
e
ef
fe
ct
Ve
ry
lo
w
ce
rt
ai
nt
y:
W
e
ha
ve
ve
ry
lit
tle
co
nf
id
en
ce
in
th
e
ef
fe
ct
es
tim
at
e:
Th
e
tr
ue
ef
fe
ct
is
lik
el
y
to
be
su
bs
ta
nt
ia
lly
di
ff
er
en
t
fr
om
th
e
es
tim
at
e
of
ef
fe
ct
Sacco et al. The Journal of Headache and Pain            (2019) 20:6 Page 22 of 33
Ta
b
le
16
Su
m
m
ar
y
of
fin
di
ng
s
ta
bl
e
fo
r
tr
ea
tm
en
t
w
ith
fre
m
an
ez
um
ab
67
5
m
g
lo
ad
in
g
do
se
+
22
5
m
g
m
on
th
ly
su
bc
ut
an
eo
us
in
je
ct
io
n
co
m
pa
re
d
w
ith
no
tr
ea
tm
en
t
fo
r
pr
ev
en
tio
n
of
ch
ro
ni
c
m
ig
ra
in
e
O
ut
co
m
es
A
nt
ic
ip
at
ed
ab
so
lu
te
ef
fe
ct
s
(9
5%
C
I)
Re
la
tiv
e
ef
fe
ct
(9
5%
C
I)
№
of
pa
rt
ic
ip
an
ts
(s
tu
di
es
)
C
er
ta
in
ty
of
th
e
ev
id
en
ce
(G
RA
D
E)
C
om
m
en
ts
Ri
sk
w
ith
pl
ac
eb
o
Ri
sk
w
ith
fre
m
an
ez
um
ab
Re
du
ct
io
n
of
m
on
th
ly
he
ad
ac
he
da
ys
fo
llo
w
up
:3
m
on
th
s
Th
e
m
ea
n
re
du
ct
io
n
of
m
on
th
ly
he
ad
ac
he
da
ys
w
as
−
2.
5
da
ys
#
Th
e
m
ea
n
re
du
ct
io
n
of
m
on
th
ly
he
ad
ac
he
da
ys
in
th
e
in
te
rv
en
tio
n
gr
ou
p
w
as
2.
1
da
ys
lo
w
er
(2
.6
lo
w
er
to
1.
5
lo
w
er
)
–
92
2
(2
RC
Ts
)
⨁
⨁
⨁
⨁
H
IG
H
Tr
ea
tm
en
t
w
ith
Fr
em
an
ez
um
ab
67
5/
22
5
m
g
re
du
ce
s
m
on
th
ly
he
ad
ac
he
da
ys
sl
ig
ht
ly
co
m
pa
re
d
to
pl
ac
eb
o.
Re
du
ct
io
n
of
m
on
th
ly
ac
ut
e
tr
ea
tm
en
t
da
ys
fo
llo
w
up
:3
m
on
th
s
Th
e
m
ea
n
re
du
ct
io
n
of
m
on
th
ly
he
ad
ac
he
da
ys
w
as
−
4.
5
da
ys
#
Th
e
m
ea
n
re
du
ct
io
n
of
m
on
th
ly
ac
ut
e
tr
ea
tm
en
t
da
ys
in
th
e
in
te
rv
en
tio
n
gr
ou
p
w
as
2.
4
da
ys
lo
w
er
(3
.4
lo
w
er
to
1.
4
lo
w
er
)
–
92
2
(2
RC
Ts
)
⨁
⨁
⨁
⨁
H
IG
H
Tr
ea
tm
en
t
w
ith
Fr
em
an
ez
um
ab
67
5/
22
5
m
g
re
du
ce
s
m
on
th
ly
ac
ut
e
tr
ea
tm
en
t
da
ys
sl
ig
ht
ly
co
m
pa
re
d
to
pl
ac
eb
o.
Im
pr
ov
em
en
t
in
fu
nc
tio
na
l
H
IT
-6
sc
or
e
fo
llo
w
up
:
3
m
on
th
s
Th
e
m
ea
n
im
pr
ov
em
en
t
in
fu
nc
tio
na
lH
IT
-6
sc
or
e
w
as
−
4.
5
po
in
ts
Th
e
m
ea
n
im
pr
ov
em
en
t
in
fu
nc
tio
na
lH
IT
-6
sc
or
e
in
th
e
in
te
rv
en
tio
n
gr
ou
p
w
as
2.
4
da
ys
fe
w
er
(3
.4
fe
w
er
to
1.
4
fe
w
er
)
–
74
6
(1
RC
T)
⨁
⨁
⨁
◯
M
ED
IU
M
a
Tr
ea
tm
en
t
w
ith
fre
m
an
ez
um
ab
67
5/
22
5
m
g
im
pr
ov
es
fu
nc
tio
na
lH
IT
-6
sc
or
e
sl
ig
ht
ly
co
m
pa
re
d
to
pl
ac
eb
o.
A
t
le
as
t
50
%
re
du
ct
io
n
of
m
on
th
ly
he
ad
ac
he
da
ys
fo
llo
w
up
:3
m
on
th
s
20
7
pe
r
10
00
43
1
pe
r
10
00
(3
50
to
53
0)
RR
2.
08
57
(1
.6
94
8
to
2.
56
67
)
92
2
(2
RC
Ts
)
⨁
⨁
⨁
⨁
H
IG
H
Tr
ea
tm
en
t
w
ith
Fr
em
an
ez
um
ab
67
5/
22
5
m
g
re
su
lts
in
at
le
as
t
50
%
re
du
ct
io
n
of
m
on
th
ly
he
ad
ac
he
da
ys
co
m
pa
re
d
to
pl
ac
eb
o.
Se
rio
us
ad
ve
rs
e
ev
en
ts
fo
llo
w
up
:1
w
ee
ks
15
pe
r
10
00
13
pe
r
10
00
(4
to
38
)
RR
0.
85
16
(0
.2
88
4
to
2.
51
50
)
92
8
(2
RC
Ts
)
⨁
⨁
⨁
⨁
H
IG
H
Tr
ea
tm
en
t
w
ith
Fr
em
an
ez
um
ab
67
5/
22
5
m
g
re
su
lts
in
an
un
im
po
rt
an
t
re
du
ct
io
n
of
se
rio
us
ad
ve
rs
e
ev
en
t
oc
cu
rr
en
ce
co
m
pa
re
d
to
pl
ac
eb
o.
M
or
ta
lit
y
fo
llo
w
up
:
3
m
on
th
s
0
pe
r
10
00
0
pe
r
10
00
(0
to
0)
no
t
es
tim
ab
le
92
8
(2
RC
Ts
)
N
o
de
at
hs
w
er
e
ob
se
rv
ed
w
ith
tr
ea
tm
en
t
w
ith
Fr
em
an
ez
um
ab
67
5/
22
5
m
g
or
pl
ac
eb
o
#T
he
ris
k
is
fr
om
a
si
ng
le
st
ud
y;
CI
:C
on
fid
en
ce
in
te
rv
al
;R
R:
Ri
sk
ra
tio
;R
C
T:
ra
nd
om
iz
ed
co
nt
ro
lle
d
tr
ia
l;
a D
ow
ng
ra
de
d
on
ce
du
e
to
in
co
ns
is
te
nc
y
G
RA
D
E
W
or
ki
ng
G
ro
up
gr
ad
es
of
ev
id
en
ce
H
ig
h
ce
rt
ai
nt
y:
W
e
ar
e
ve
ry
co
nf
id
en
t
th
at
th
e
tr
ue
ef
fe
ct
lie
s
cl
os
e
to
th
at
of
th
e
es
tim
at
e
of
th
e
ef
fe
ct
M
od
er
at
e
ce
rt
ai
nt
y:
W
e
ar
e
m
od
er
at
el
y
co
nf
id
en
t
in
th
e
ef
fe
ct
es
tim
at
e:
Th
e
tr
ue
ef
fe
ct
is
lik
el
y
to
be
cl
os
e
to
th
e
es
tim
at
e
of
th
e
ef
fe
ct
,b
ut
th
er
e
is
a
po
ss
ib
ili
ty
th
at
it
is
su
bs
ta
nt
ia
lly
di
ff
er
en
t
Lo
w
ce
rt
ai
nt
y:
O
ur
co
nf
id
en
ce
in
th
e
ef
fe
ct
es
tim
at
e
is
lim
ite
d:
Th
e
tr
ue
ef
fe
ct
m
ay
be
su
bs
ta
nt
ia
lly
di
ff
er
en
t
fr
om
th
e
es
tim
at
e
of
th
e
ef
fe
ct
Ve
ry
lo
w
ce
rt
ai
nt
y:
W
e
ha
ve
ve
ry
lit
tle
co
nf
id
en
ce
in
th
e
ef
fe
ct
es
tim
at
e:
Th
e
tr
ue
ef
fe
ct
is
lik
el
y
to
be
su
bs
ta
nt
ia
lly
di
ff
er
en
t
fr
om
th
e
es
tim
at
e
of
ef
fe
ct
Sacco et al. The Journal of Headache and Pain            (2019) 20:6 Page 23 of 33
Ta
b
le
17
Su
m
m
ar
y
of
fin
di
ng
s
ta
bl
e
fo
r
tr
ea
tm
en
t
w
ith
ga
lc
an
ez
um
ab
12
0
m
g
co
m
pa
re
d
w
ith
no
tr
ea
tm
en
t
fo
r
pr
ev
en
tio
n
of
ch
ro
ni
c
m
ig
ra
in
e
O
ut
co
m
es
A
nt
ic
ip
at
ed
ab
so
lu
te
ef
fe
ct
s
(9
5%
C
I)
Re
la
tiv
e
ef
fe
ct
(9
5%
C
I)
№
of
pa
rt
ic
ip
an
ts
(s
tu
di
es
)
C
er
ta
in
ty
of
th
e
ev
id
en
ce
(G
RA
D
E)
C
om
m
en
ts
Ri
sk
w
ith
pl
ac
eb
o
Ri
sk
w
ith
ga
lc
an
ez
um
ab
Re
du
ct
io
n
of
m
on
th
ly
m
ig
ra
in
e
da
ys
fo
llo
w
up
:
3
m
on
th
s
Th
e
m
ea
n
re
du
ct
io
n
of
m
on
th
ly
he
ad
ac
he
da
ys
w
as
−
2.
7
da
ys
Th
e
m
ea
n
re
du
ct
io
n
of
m
on
th
ly
he
ad
ac
he
da
ys
in
th
e
in
te
rv
en
tio
n
gr
ou
p
w
as
2.
1
da
ys
lo
w
er
(2
.9
lo
w
er
to
1.
3
lo
w
er
)
–
83
6
(1
RC
T)
⨁
⨁
⨁
◯
M
ED
IU
M
a
Tr
ea
tm
en
t
w
ith
G
al
ca
ne
zu
m
ab
12
0
m
g
re
du
ce
s
m
on
th
ly
m
ig
ra
in
e
da
ys
sl
ig
ht
ly
co
m
pa
re
d
to
pl
ac
eb
o.
Re
du
ct
io
n
of
m
on
th
ly
ac
ut
e
tr
ea
tm
en
t
da
ys
fo
llo
w
up
:
3
m
on
th
s
Th
e
m
ea
n
re
du
ct
io
n
of
m
on
th
ly
he
ad
ac
he
da
ys
w
as
−
2.
2
da
ys
Th
e
m
ea
n
re
du
ct
io
n
of
m
on
th
ly
ac
ut
e
tr
ea
tm
en
t
da
ys
in
th
e
in
te
rv
en
tio
n
gr
ou
p
w
as
2.
5
da
ys
lo
w
er
(3
.3
lo
w
er
to
1.
8
lo
w
er
)b
–
83
6
(1
RC
T)
⨁
⨁
⨁
◯
M
ED
IU
M
a
Tr
ea
tm
en
t
w
ith
G
al
ca
ne
zu
m
ab
12
0
m
g
re
du
ce
s
m
on
th
ly
ac
ut
e
tr
ea
tm
en
t
da
ys
sl
ig
ht
ly
co
m
pa
re
d
to
pl
ac
eb
o.
Im
pr
ov
em
en
t
in
fu
nc
tio
na
l
M
ID
A
S
sc
or
e
fo
llo
w
up
:
3
m
on
th
s
Th
e
m
ea
n
im
pr
ov
em
en
t
in
fu
nc
tio
na
lM
ID
A
S
sc
or
e
w
as
−
11
.5
po
in
ts
Th
e
m
ea
n
im
pr
ov
em
en
t
in
fu
nc
tio
na
l
M
ID
A
S
sc
or
e
in
th
e
in
te
rv
en
tio
n
gr
ou
p
w
as
8.
7
po
in
ts
lo
w
er
(1
6.
4
lo
w
er
to
1.
1
lo
w
er
)
–
83
6
(1
RC
T)
⨁
⨁
⨁
◯
M
ED
IU
M
a
Tr
ea
tm
en
t
w
ith
G
al
ca
ne
zu
m
ab
12
0
m
g
im
pr
ov
es
fu
nc
tio
na
lM
ID
A
S
sc
or
e
co
m
pa
re
d
to
pl
ac
eb
o.
A
t
le
as
t
50
%
re
du
ct
io
n
of
m
on
th
ly
m
ig
ra
in
e
da
ys
fo
llo
w
up
:3
m
on
th
s
14
9
pe
r
10
00
28
4
pe
r
10
00
(2
15
to
37
5)
RR
1.
91
12
(1
.4
47
7
to
2.
52
32
)
83
6
(1
RC
T)
⨁
⨁
⨁
◯
M
ED
IU
M
a
Tr
ea
tm
en
t
w
ith
G
al
ca
ne
zu
m
ab
12
0
m
g
m
g
re
su
lts
in
at
le
as
t
50
%
re
du
ct
io
n
of
m
on
th
ly
he
ad
ac
he
da
ys
co
m
pa
re
d
to
pl
ac
eb
o.
Se
rio
us
ad
ve
rs
e
ev
en
ts
fo
llo
w
up
:3
m
on
th
s
7
pe
r
10
00
4
pe
r
10
00
(0
to
34
)
RR
0.
52
88
(0
.0
59
4
to
4.
70
92
)
83
6
(1
RC
T)
⨁
⨁
⨁
◯
M
ED
IU
M
a
Tr
ea
tm
en
t
w
ith
G
al
ca
ne
zu
m
ab
12
0
m
g
m
g
re
su
lts
in
a
po
ss
ib
ly
un
im
po
rt
an
t
ef
fe
ct
on
se
rio
us
ad
ve
rs
e
ev
en
t
oc
cu
rr
en
ce
co
m
pa
re
d
to
pl
ac
eb
o.
M
or
ta
lit
y
fo
llo
w
up
:3
m
on
th
s
0
pe
r
10
00
0
pe
r
10
00
(0
to
0)
no
t
es
tim
ab
le
83
6
(1
RC
T)
N
o
de
at
hs
w
er
e
ob
se
rv
ed
w
ith
tr
ea
tm
en
t
w
ith
G
al
ca
ne
zu
m
ab
12
0
m
g
or
pl
ac
eb
o
CI
C
on
fid
en
ce
in
te
rv
al
,R
R
Ri
sk
ra
tio
,R
CT
Ra
nd
om
iz
ed
co
nt
ro
lle
d
tr
ia
l;
a D
ow
ng
ra
de
d
on
ce
du
e
to
in
co
ns
is
te
nc
y;
b
no
m
in
al
ls
ig
ni
fic
an
ce
,n
on
-s
ig
ni
fic
an
t
af
te
r
m
ul
tip
lic
ity
ad
ju
st
m
en
ts
G
RA
D
E
W
or
ki
ng
G
ro
up
gr
ad
es
of
ev
id
en
ce
H
ig
h
ce
rt
ai
nt
y:
W
e
ar
e
ve
ry
co
nf
id
en
t
th
at
th
e
tr
ue
ef
fe
ct
lie
s
cl
os
e
to
th
at
of
th
e
es
tim
at
e
of
th
e
ef
fe
ct
M
od
er
at
e
ce
rt
ai
nt
y:
W
e
ar
e
m
od
er
at
el
y
co
nf
id
en
t
in
th
e
ef
fe
ct
es
tim
at
e:
Th
e
tr
ue
ef
fe
ct
is
lik
el
y
to
be
cl
os
e
to
th
e
es
tim
at
e
of
th
e
ef
fe
ct
,b
ut
th
er
e
is
a
po
ss
ib
ili
ty
th
at
it
is
su
bs
ta
nt
ia
lly
di
ff
er
en
t
Lo
w
ce
rt
ai
nt
y:
O
ur
co
nf
id
en
ce
in
th
e
ef
fe
ct
es
tim
at
e
is
lim
ite
d:
Th
e
tr
ue
ef
fe
ct
m
ay
be
su
bs
ta
nt
ia
lly
di
ff
er
en
t
fr
om
th
e
es
tim
at
e
of
th
e
ef
fe
ct
Ve
ry
lo
w
ce
rt
ai
nt
y:
W
e
ha
ve
ve
ry
lit
tle
co
nf
id
en
ce
in
th
e
ef
fe
ct
es
tim
at
e:
Th
e
tr
ue
ef
fe
ct
is
lik
el
y
to
be
su
bs
ta
nt
ia
lly
di
ff
er
en
t
fr
om
th
e
es
tim
at
e
of
ef
fe
ct
Sacco et al. The Journal of Headache and Pain            (2019) 20:6 Page 24 of 33
Ta
b
le
18
Su
m
m
ar
y
of
fin
di
ng
s
ta
bl
e
fo
r
tr
ea
tm
en
t
w
ith
ga
lc
an
ez
um
ab
24
0
m
g
co
m
pa
re
d
w
ith
no
tr
ea
tm
en
t
fo
r
pr
ev
en
tio
n
of
ch
ro
ni
c
m
ig
ra
in
e
O
ut
co
m
es
A
nt
ic
ip
at
ed
ab
so
lu
te
ef
fe
ct
s
(9
5%
C
I)
Re
la
tiv
e
ef
fe
ct
(9
5%
C
I)
№
of
pa
rt
ic
ip
an
ts
(s
tu
di
es
)
C
er
ta
in
ty
of
th
e
ev
id
en
ce
(G
RA
D
E)
C
om
m
en
ts
Ri
sk
w
ith
pl
ac
eb
o
Ri
sk
w
ith
ga
lc
an
ez
um
ab
Re
du
ct
io
n
of
m
on
th
ly
m
ig
ra
in
e
da
ys
fo
llo
w
up
:3
m
on
th
s
Th
e
m
ea
n
re
du
ct
io
n
of
m
on
th
ly
he
ad
ac
he
da
ys
w
as
−
2.
7
da
ys
Th
e
m
ea
n
re
du
ct
io
n
of
m
on
th
ly
he
ad
ac
he
da
ys
in
th
e
in
te
rv
en
tio
n
gr
ou
p
w
as
1.
9
da
ys
lo
w
er
(2
.7
lo
w
er
to
1.
1
lo
w
er
)
–
83
5
(1
RC
T)
⨁
⨁
⨁
◯
M
ED
IU
M
a
Tr
ea
tm
en
t
w
ith
G
al
ca
ne
zu
m
ab
24
0
m
g
re
du
ce
s
m
on
th
ly
m
ig
ra
in
e
da
ys
sl
ig
ht
ly
co
m
pa
re
d
to
pl
ac
eb
o.
Re
du
ct
io
n
of
m
on
th
ly
ac
ut
e
tr
ea
tm
en
t
da
ys
fo
llo
w
up
:
3
m
on
th
s
Th
e
m
ea
n
re
du
ct
io
n
of
m
on
th
ly
he
ad
ac
he
da
ys
w
as
−
2.
2
da
ys
Th
e
m
ea
n
re
du
ct
io
n
of
m
on
th
ly
ac
ut
e
tr
ea
tm
en
t
da
ys
in
th
e
in
te
rv
en
tio
n
gr
ou
p
w
as
2.
0
da
ys
lo
w
er
(2
.8
lo
w
er
to
1.
3
lo
w
er
)
–
83
5
(1
RC
T)
⨁
⨁
⨁
◯
M
ED
IU
M
a
Tr
ea
tm
en
t
w
ith
G
al
ca
ne
zu
m
ab
24
0
m
g
re
du
ce
s
m
on
th
ly
ac
ut
e
tr
ea
tm
en
t
da
ys
sl
ig
ht
ly
co
m
pa
re
d
to
pl
ac
eb
o.
Im
pr
ov
em
en
t
in
fu
nc
tio
na
l
M
ID
A
S
sc
or
e
fo
llo
w
up
:
3
m
on
th
s
Th
e
m
ea
n
im
pr
ov
em
en
t
in
fu
nc
tio
na
lM
ID
A
S
sc
or
e
w
as
−
11
.5
po
in
ts
Th
e
m
ea
n
im
pr
ov
em
en
t
in
fu
nc
tio
na
l
M
ID
A
S
sc
or
e
in
th
e
in
te
rv
en
tio
n
gr
ou
p
w
as
5.
5
po
in
ts
lo
w
er
(1
3.
1
lo
w
er
to
2.
1
hi
gh
er
)
–
83
5
(1
RC
T)
⨁
⨁
⨁
◯
M
ED
IU
M
a
Tr
ea
tm
en
t
w
ith
G
al
ca
ne
zu
m
ab
24
0
m
g
do
es
no
t
im
pr
ov
e
fu
nc
tio
na
lM
ID
A
S
sc
or
e
si
gn
ifi
ca
nt
ly
co
m
pa
re
d
to
pl
ac
eb
o.
A
t
le
as
t
50
%
re
du
ct
io
n
of
m
on
th
ly
m
ig
ra
in
e
da
ys
fo
llo
w
up
:3
m
on
th
s
14
9
pe
r
10
00
28
5
pe
r
10
00
(2
16
to
37
7)
RR
1.
91
81
(1
.4
53
1
to
2.
53
21
)
83
5
(1
RC
T)
⨁
⨁
⨁
◯
M
ED
IU
M
a
Tr
ea
tm
en
t
w
ith
G
al
ca
ne
zu
m
ab
24
0
m
g
m
g
re
su
lts
in
at
le
as
t
50
%
re
du
ct
io
n
of
m
on
th
ly
he
ad
ac
he
da
ys
co
m
pa
re
d
to
pl
ac
eb
o.
Se
rio
us
ad
ve
rs
e
ev
en
ts
fo
llo
w
up
:3
m
on
th
s
7
pe
r
10
00
19
pe
r
10
00
(5
to
70
)
RR
2.
65
34
(0
.7
18
1
to
9.
80
49
)
83
5
(1
RC
T)
⨁
⨁
⨁
◯
M
ED
IU
M
a
Tr
ea
tm
en
t
w
ith
G
al
ca
ne
zu
m
ab
24
0
m
g
m
g
re
su
lts
in
a
po
ss
ib
ly
un
im
po
rt
an
t
ef
fe
ct
on
se
rio
us
ad
ve
rs
e
ev
en
t
oc
cu
rr
en
ce
co
m
pa
re
d
to
pl
ac
eb
o.
M
or
ta
lit
y
fo
llo
w
up
:3
m
on
th
s
0
pe
r
10
00
0
pe
r
10
00
(0
to
0)
no
t
es
tim
ab
le
83
5
(1
RC
T)
N
o
de
at
hs
w
er
e
ob
se
rv
ed
w
ith
tr
ea
tm
en
t
w
ith
G
al
ca
ne
zu
m
ab
24
0
m
g
or
pl
ac
eb
o
CI
C
on
fid
en
ce
in
te
rv
al
,R
R
Ri
sk
ra
tio
,R
CT
Ra
nd
om
iz
ed
co
nt
ro
lle
d
tr
ia
l;
a D
ow
ng
ra
de
d
on
ce
du
e
to
in
co
ns
is
te
nc
y
G
RA
D
E
W
or
ki
ng
G
ro
up
gr
ad
es
of
ev
id
en
ce
H
ig
h
ce
rt
ai
nt
y:
W
e
ar
e
ve
ry
co
nf
id
en
t
th
at
th
e
tr
ue
ef
fe
ct
lie
s
cl
os
e
to
th
at
of
th
e
es
tim
at
e
of
th
e
ef
fe
ct
M
od
er
at
e
ce
rt
ai
nt
y:
W
e
ar
e
m
od
er
at
el
y
co
nf
id
en
t
in
th
e
ef
fe
ct
es
tim
at
e:
Th
e
tr
ue
ef
fe
ct
is
lik
el
y
to
be
cl
os
e
to
th
e
es
tim
at
e
of
th
e
ef
fe
ct
,b
ut
th
er
e
is
a
po
ss
ib
ili
ty
th
at
it
is
su
bs
ta
nt
ia
lly
di
ff
er
en
t
Lo
w
ce
rt
ai
nt
y:
O
ur
co
nf
id
en
ce
in
th
e
ef
fe
ct
es
tim
at
e
is
lim
ite
d:
Th
e
tr
ue
ef
fe
ct
m
ay
be
su
bs
ta
nt
ia
lly
di
ff
er
en
t
fr
om
th
e
es
tim
at
e
of
th
e
ef
fe
ct
Ve
ry
lo
w
ce
rt
ai
nt
y:
W
e
ha
ve
ve
ry
lit
tle
co
nf
id
en
ce
in
th
e
ef
fe
ct
es
tim
at
e:
Th
e
tr
ue
ef
fe
ct
is
lik
el
y
to
be
su
bs
ta
nt
ia
lly
di
ff
er
en
t
fr
om
th
e
es
tim
at
e
of
ef
fe
ct
Sacco et al. The Journal of Headache and Pain            (2019) 20:6 Page 25 of 33
refractory disease such as those who had not had a re-
sponse to two clusters of preventive medications.
Clinical question 1 When should treatment with CGRP
mAbs be offered to patients with migraine?
Analysis of evidence
Characteristics of patients according to migraine dur-
ation and previous use of preventive drugs is reported in
Tables 1 and 2. In all the trials, included patients had a
long migraine history less than 15 years. RCTs included
patients who had not tried any previous preventive strat-
egy, patients who had failed or not tolerated other pre-
ventatives. Patients considered as drug-resistant where
on the other hand excluded.
Referring to the RCTs on EM, the phase II RCT on
eptinezumab did not exclude patients according to pre-
vious failure of preventive drugs [32]. All the others
RCTs in EM excluded patients who failed 2 to 4 categor-
ies of preventive drugs. For erenumab, patients who had
previous medication failure represented 26% to 40% [35,
36, 44], for fremanezumab they were 27–33% [27, 34]
and for galcanezumab 18–19% [33–43]. A phase IIIb
study, the LIBERTY trial, evaluated the efficacy of erenu-
mab 140 mg monthly dose as compared to placebo in
patients with EM who had been treated unsuccessfully
(in terms of either efficacy or tolerability, or both) with
between two and four preventive treatments [50]. At 3
months, significantly more patients in the erenumab
group than in the placebo group had a 50% or greater
reduction from baseline in the mean number of monthly
migraine days. Erenumab was also significantly more ef-
ficacious than placebo for all secondary endpoints, in-
cluding improvements in migraine frequency,
medication use, and functional outcomes.
Referring to the RCTs on CM, the phase II RCT on
erenumab, excluded patients who had no therapeutic re-
sponse on an adequate trial of > 3 preventive medica-
tions [45]. In the overall study population, 74% of
patients had previously received preventive treatments
[25]; among them, 48 to 50% of patients had failed ≥2
preventive drugs, 66 to 70% had failed > 1 preventive
drug and 30 to 34% had no drug failure; 47 to 52% of
patients had previous use of topiramate. Onabotulinum-
toxinA injections for migraine prevention were prohib-
ited during the study and for at least 4 months before
the start of the baseline phase; 23 to 26% of patients had
used onabotulinumtoxinA before study entry. MOH was
explicitly allowed. Mean monthly acute migraine-specific
drug use days was around 9. Treatment differences for
erenumab versus placebo were numerically greater in
patients with ≥1 or ≥ 2 failed preventive medications
than in patients with no prior treatment failure, particu-
larly for the 140 mg dose [25]. The effect was
attributable to a lower placebo effect in patients with
prior medications failure than in patients without medi-
cations failure.
The phase II and III RCTs on fremanezumab in CM
excluded patients who had no therapeutic response of
≥2 preventive medications [26, 41]. The phase III study
explicitly excluded patients with unremitting headaches
(headaches for more than 80% of the time they were
awake, and less than 4 days without headache per
month); daily headache was acceptable if patients had
headaches on less than 80% of the time they were awake
on most days [41]. In the study, 28 to 31% of patients
had previous use of topiramate. In both trials, onabotuli-
numtoxinA injections were prohibited during the study
and in the 4 [41] or 6 [26] months before study entry. In
the phase III study, 13 to 18% of patients had used ona-
botulinumtoxinA before study entry [41]. Patients with
medication overuse headache (MOH) were allowed in
the study [26, 41]. Days of acute drug use per month
ranged from 15 to 16 in one study [26] whereas mean
28-day days of use of any acute headache medications
was around 13 in the other study [41].
The phase III RCT on galcanezumab in CM excluded
patients who had no therapeutic response of > 3 pre-
ventive medications [31]. OnabotulinumtoxinA injec-
tions were prohibited during the study. Patients who had
failed 2 or 3 previous preventive treatments represented
24–35% of the study population. Patients with MOH
were allowed in the study and represented 63–64% of all
the study population. In this study patients without
headache free days were excluded.
Clinical guidance
In EM, CGRP mAbs were evaluated both in patients
with and without previous drug failure. So far, in most
of the available phase II and phase III RCTs, participants
with previous failure of as few as 2 preventive medica-
tion classes for migraine were excluded. This implies
that efficacy can be different for patients with severe,
treatment-resistant migraine. Only in the LIBERTY study
on erenumab 140 mg monthly patients treated unsuc-
cessfully with between two and four preventive treat-
ments were included. The study confirmed effectiveness
of erenumab in this subgroup of patients. However, no
results were provided for patients stratified according to
previous preventive failure versus non tolerability.
In CM, erenumab, fremanezumab, and galcanezumab
were evaluated both in patients with and without previous
drug failure. Data on erenumab indicated that the drug is
effective even in patients with failure to previous drugs. Pa-
tients who had previous use of onabotulinumtoxinA were
included in RCTs but no information referring to previous
efficacy of onabotulinumtoxinA and response to study
treatment is available. Erenumab, fremanezumab, and
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galcanezumab were not evaluated in patients with CM re-
fractory to current available medical treatments. However,
due to the poor quality of life of patients with refractory
CM it is reasonable to treat them in daily clinical practice
with erenumab, fremanezumab, or galcanezumab. Post-
marketing studies are needed to provide information about
efficacy of CGRP mAbs in refractory CM.
Costs of the CGRP mAbs are not yet entirely known but
they will be higher as compared to costs of the other avail-
able drugs. Pharmacogenomics studies should provide ana-
lyses to consider the economic impact of those drugs
taking into account the overall direct and indirect costs re-
lated to untreated migraine or to migraine treated with the
available drugs. Differences in reimbursement and regula-
tions among countries will probably be present. Efficacy,
safety, good tolerability profile and ease of use may repre-
sent advantages of CGRP mAbs drugs which may lead pa-
tients to prefer those drugs as first-line options. Rather
than only efficacy, CGRP mAbs have advantages referring
to side effects and treatment administration. Poor response
in patients with migraine may also be attributed to lack of
compliance to available medical treatments because of the
need of taking multiple doses of the drugs or side effects.
CGRP mAbs may represent suitable options for patients
who have contraindications to other preventive treatments
because of comorbidities or side effects and in patients who
have poor compliance to other treatments where strategies
to improve compliance have failed. However, due to high
costs it will not be possible to offer those drugs to all pa-
tients with migraine requiring preventive treatment. At the
moment, limiting prescription to patients with prior drug
failure may represent a reasonable option until pharmaeco-
nomics studies will provide more data. It is important to
point out that patients with multiple drug failures were
mostly excluded by RCTs. It is important to note that early
treatment of patients with high frequency EM may prevent
CM with important impact on individuals and society.
Final recommendations based on experts’ opinions are
reported in Table 19.
Clinical question 2 How should other preventive treat-
ments be managed when using CGRP mAbs in patients
with migraine?
Analysis of evidence
Summary about concomitant preventive treatments in
the RCTs is available in Tables 1 and 2. In the RCT with
eptinezumab, preventive drugs were not allowed [32]. In
the phase II RCTs on erenumab in EM and CM prevent-
ive treatments were not allowed [44, 45] whereas in the
phase III RCTs preventatives were allowed but a low
proportion of patients (2–7%) had concomitant use [35,
36]. All RCTs on fremanezumab allowed the inclusion of
those patients [26, 27, 34, 41]. Concomitant users of
preventive drugs ranged from 20 to 34% for EM [27, 34]
and from 20 to 43% for CM [26, 41]. Notably, a
sub-analysis of patients using fremanezumab as an
add-on treatment [30] and pooling together data of pa-
tients with EM and CM showed that among patients
who received fremanezumab as add-on to their prevent-
ive treatment there was a significant decrease in the
number of migraine days relative to placebo (− 4.1 ver-
sus − 2.5), an increase in the number of patients who
had improvement by 50% or more of migraine days
(40% versus 24%; P = 0.0505) and a reduction in the
mean number of days using acute medications (33% vs
26%). Patients who were taking oral preventive drugs
were not included in the RCTs on galcanezumab in EM
[33, 42, 43] but were allowed in the RCT in CM [31].
Clinical guidance
We have scarce information on how to manage other
oral preventive treatments in association with
anti-CGRP mAb in patients with migraine. No inter-
action is supposed by CGRP mAbs and available pre-
ventive treatments. Data on erenumab and
fremanezumab suggest that the two drugs are beneficial
also when added to ongoing oral preventive treatment.
Combined use of other prophylactics and CGRP mAbs
may be considered in patients with insufficient response
to a single type prophylactics. If patients are on prevent-
ive drugs that do have some but not sufficient effect,
anti-CGRP antibodies can be added because no inter-
action is expected. When a possible efficacy of
anti-CGRP mAb is established in a given patient it
should be discussed with the patient whether withdrawal
from the oral prophylactic drug should be tried.
In patients with CM, it is reasonable not to stop
current ongoing migraine preventive drugs in patients
before initiating the use of erenumab, fremanezumab, or
galcanezumab in order to avoid possible rebound effects.
Withdrawal of other preventive drugs may be done later
in patients showing favorable clinical response after
starting anti-CGRP mAb. A further point is to clarify, in
patients with CM who had favorable response to
anti-CGRP mAb but who may continue to experience a
significant burden of migraine attacks if adding-on any
preventive strategy may further improve attacks fre-
quency, attacks severity, use of preventive drugs and
quality of life. At the moment, no such information is
available but it is reasonable to allow the use of add-
itional preventive drugs where prevention with
anti-CGRP mAb is still considered not optimal.
No information on current use of erenumab, fremane-
zumab, and galcanezumab with onabotulinumtoxinA is
available and this association is not supported at the mo-
ment. For those patients who are on botulinum toxin
and who show an inadequate response, withdrawal of
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onabotulinumtoxinA with start of the anti-CGRP mAb
may be considered. While in the trials there were time
restriction referring to onabotulinumtoxinA withdrawal
and start of the anti-CGRP mAb, they represented pro-
cedures to avoid confounders and are not reasonable in
daily clinical practice. At the moment, we do not know
whether it is reasonable to consider combining onabotu-
linumtoxinA with anti-CGRP mAb in patients who have
a suboptimal response to each of those drugs.
Final recommendations based on experts’ opinions are
reported in Table 19.
Clinical question 3 When should treatment with CGRP
mAbs be stopped in patients with migraine?
Analysis of evidence
For eptinezumab duration of treatment in the available
RCT was 3 months [32].
For erenumab in available RCTs duration of treatment
ranged from 3months to 6 months for EM and from 3
months to 3months for CM [35, 36, 44, 45]. In the
open-label extension of the phase II RCT in EM in pa-
tients who had completed the 1-year open-label
follow-up, persistent benefits were reported for patients
who continued treatment up to 1 year [24]. There was a
fatal event related to atherosclerosis and a non-fatal
myocardial ischemia in patients treated with erenumab
70mg [24]. The fatal event was considered not related
to erenumab while for the other event conclusion was
uncertain. A post-hoc analysis of data form the STRIVE
and the phase II study in CM, showed evidence of onset
of efficacy of erenumab during the first week of treat-
ment [40]. At week 1, 43% of EM patients and 26% of
CM patients in the erenumab 140 mg group experienced
a ≥ 50% reduction in weekly migraine days (15% increase
vs placebo for EM and 10% increase vs placebo for CM).
For fremanezumab duration of treatment was of 3
Table 19 Recommendations about the use of anti-calcitonin gene-related peptide monoclonal antibodies in subjects with migraine
Clinical
question
Recommendation Strength of the
recommendation
1. When should treatment with anti-CGRP monoclonal antibodies be offered to patients with migraine?
In patients with episodic migraine who have failed at least two of the available medical treatments
or who cannot use other preventive treatments because of comorbidities, side effects or poor
compliance, we suggest the use of erenumab, fremanezumab, or galcanezumab
In patients with chronic migraine who have failed at least two of the available medical treatments
or who cannot use other preventive treatments because of comorbidities, side effects or poor
compliance, we suggest the use of erenumab, fremanezumab, or galcanezumab
Experts’ opinion
2. How should other preventive treatments be managed when using anti-CGRP monoclonal antibodies in patients with migraine?
In patients with episodic migraine, before starting erenumab, galcanezumab or fremanezumab we
suggest to stop oral preventive drugs unless the patient had a previous history of chronic migraine
before prevention; in this case, we suggest to add the anti-CGRP monoclonal antibody to the ongoing
treatment and to re-assess the need of treatment withdrawal
In patients with chronic migraine who are on treatment with any oral drug with inadequate treatment
response we suggest to add erenumab, fremanezumab, or galcanezumab and to consider later withdrawal
of the oral drug
In patients with chronic migraine who are on treatment with onabotulinumtoxinA with inadequate treatment
response we suggest to stop onabotulinumtoxinA before initiation of erenumab, fremanezumab, or galcanezumab
In patients with chronic migraine who are on treatment with erenumab, fremanezumab, or galcanezumab and
who may benefit from additional prevention we suggest to add oral preventive drugs
Experts’ opinion
3. When should treatment with anti-CGRP monoclonal antibodies be stopped in patients with migraine?
In patients with episodic migraine, we suggest to consider to stop treatment with erenumab, fremanezumab,
and galcanezumab after 6–12months of treatments
In patients with chronic migraine, we suggest to consider to stop treatment with erenumab, fremanezumab,
and galcanezumab after 6–12months of treatments
Experts’ opinion
4. Should medication overuse be treated before offering treatment anti-CGRP monoclonal antibodies to patients with chronic migraine?
In patients with chronic migraine and medication overuse, we suggest to use erenumab, fremanezumab,
and galcanezumab before or after withdrawal of acute medications
Experts’ opinion
5. In which patients anti-CGRP monoclonal antibodies are not to be used?
In patients with migraine, we suggest to avoid anti-CGRP monoclonal antibodies in pregnant or nursing
women, in individuals with alcohol or drug abuse, cardio and cerebrovascular diseases, and with severe
mental disorders
Experts’ opinion
6. Should binding and/or neutralizing antibodies be monitored?
In patients with migraine on treatment with anti-CGRP monoclonal antibodies, we suggest not to test
binding and/or neutralizing antibodies in daily clinical practice; we suggest to further study the possible
implications of binding and/or neutralizing antibodies
Experts’ opinion
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months in all the trials in EM and CM [26, 27, 34, 41].
A post-hoc analysis of patients treated with fremanezu-
mab in the phase II studies indicated that fremanezumab
may be associated with sustained efficacy in a substantial
percentage of those who show an initial response; sus-
tained response is less obvious in patients with CM than
in patients with EM [37]. For galcanezumab duration of
treatment in available RCTs in EM was from 3 up to 6
months [31, 33, 42, 43]. A pooled analysis of data on gal-
canezumab in patients with EM (EVOLVE-1 and
EVOLVE-2 parallel studies) or CM (REGAIN study) ex-
amined the likelihood of response with continued galca-
nezumab treatment in patients with EM or CM without
initial clinical improvement [49]. In patients with EM
having “modest” early improvement at month 1, 62%
achieved “good” and 20% achieved “better” responses
with continued treatment. A percentage of patients with
“limited” (43%) or “minimal/no” (34%) early improve-
ment, or “worsening” (20%;) achieved a “good” response
after continued treatment. In patients with CM, having
“modest” early improvement, 38% achieved “good” and
13% “better” responses with continued treatment. A
“good” response was achieved for a percentage of pa-
tients with “minimal/no” early improvement (17%).
Similar patterns were observed for those without clinical
response at month 2, though percentages were lower.
An open label study which evaluated safety and toler-
ability of galcanezumab 120 and 240 mg in patients with
episodic and chronic migraine provided information on
treatment at 1-year. In the study authors found high
study completion rate (77.8%) supporting the tolerability
of the study drug through all 12 months of treatment
[47]. In patients who completed the study, treatment
compliance was > 95%. Furthermore, the percentage of
discontinuations due to adverse events was low (< 5%
combined doses), and few SAEs occurred (< 4% com-
bined doses, and none considered related to treatment).
A further analysis from this same study indicated that
treatment with galcanezumab led to high levels of satis-
faction and high levels of preference and less side effects
versus previous treatments [48].
Clinical guidance
As a general rule, treatment can be stopped if migraine
is considered too infrequent to justify preventive treat-
ment or if treatment is considered not effective.
Data from the available trials suggest that the effective re-
duction of monthly headache or migraine days due to treat-
ment with CGRP mAbs may be observed very early, after
less than one month from the first dose. Data from RCTs
suggest that patients may have additional benefits with con-
tinuation of treatment and that some patients who have
worsening with treatment or who are considered
non-responders may have improvement with continuation
of treatment. For those reason it is reasonable not to stop
treatment before 3months even in the absence of a clinical
response. Further studies are needed to better assess whether
some patients might have even a more delayed response to
CGRP mAbs, and to provide information about the durabil-
ity of the response to treatment with CGRP mAbs. Further
data are also needed to clarify whether the response may be
sustained even after withdrawal of the CGRP mAbs. For the
moment it is reasonable to manage the duration of treatment
with CGRP mAbs not differently to other available prevent-
ive strategies and to continue it for at least 6–12 in patients
who have beneficial effects with those drugs.
Factors contributing to response/nonresponse have yet
to be elucidated and clinical judgment should be exer-
cised when deciding whether to discontinue treatment.
Tachyphylaxis of preventive treatments for migraine is
a frequent problem in the clinical setting. A post-hoc
analysis of patients treated with fremanezumab in the
phase II study supported a sustained efficacy, over the
3-month trial period, in a substantial percentage of those
who show an initial response [37]. One-year interim
analysis of a phase II study of erenumab 70 mg suggest
that benefits persist over time [24].
Final recommendations based on experts’ opinions are
reported in Table 19.
Clinical question 4 Should medication overuse be
treated before offering treatment CGRP mAbs to pa-
tients with CM?
Analysis of evidence
All the available RCTs on CM included patients with
MOH [26, 31, 41, 45]. No subgroup analysis of efficacy
and safety was performed for patients with MOH.
Clinical guidance
We have no direct data about the impact of MOH on the
treatment of CM with CGRP mAbs. However, the available
RCTs of erenumab, fremanezumab, and galcanezumab all
enrolled consistent proportions of patients with untreated
MOH. Therefore, it might be reasonable to offer treatment
with CGRP mAbs to patients with MOH. We have, at this
moment, no evidence to indicate that the effect of CGRP
mAbs is increased if preceded by detoxification and further
research is needed on this issue. Some adopt withdrawal
strategies before offering preventive medications to patients
with CM and MOH and some of the available evidence in-
dicate that detoxification is feasible and effective [53]. How-
ever, detoxification is not easy and feasible with all patients
and dedicated resources, which are not always available, are
needed. We have no data which indicate if the use of CGRP
mAbs may favor detoxification in patients with CM and
MOH. Of note, the frequent use of butalbital-containing
medications was an exclusion criterion from the trials;
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therefore, current evidence suggests avoiding the overuse of
butalbital before starting treatment with CGRP mAbs.
Final recommendations based on experts’ opinions are
reported in Table 19.
Clinical question 5 In which patients CGRP mAbs are
not to be used?
Analysis of evidence
Criteria varied across trial but pregnant or nursing
women, alcohol or drug abuse, cardio and cerebrovascu-
lar diseases, and severe mental disorders were the most
relevant conditions.
Clinical guidance
CGRP mAbs are unlikely to produce drug interactions
or affect the course of ongoing disease which may be
particularly relevant in patients with comorbidities.
CGRP is the most potent vasodilator peptide known [54]
and has been theoretically considered as dangerous in
patients with diseases of the vascular system. In the car-
diovascular system, CGRP is present in nerve fibres that
innervate blood vessels and the heart and participates in
the regulation of blood pressure [55]. For this reason,
patients with cardio and cerebrovascular disease were
excluded from available clinical trials. In available stud-
ies, there is no evidence of increased cardiovascular
events or any other serious concerns. However, the dur-
ation of available studies is much shorter than the dur-
ation in the clinical settings and registries should record
any SAEs to see the long-term effects of continuous
blockade of the CGRP pathway.
Additionally, there was no effect on treadmill exercise
time in patients with angina who received telcagepant, a
small-molecule CGRP antagonist [56]. These results
supplement those from a placebo-controlled study of
erenumab in a high-risk population of patients with
stable angina with a median age of 65 years, in which in-
hibition of the canonical CGRP receptor with erenumab
did not adversely affect total exercise time in a treadmill
test, among other safety endpoints [57].
Long-term safety studies with CGRP mAbs are needed to
further characterize potential cardiovascular effects. More data
from migraine patients with comorbid cardiovascular condi-
tions in a real-world setting may help further assess the theor-
etical cardiovascular risk of blocking the CGRP pathway.
Final recommendations based on experts’ opinions are
reported in Table 19.
Table 20 Binding or neutralizing antibodies directed against anti-CGRP monoclonal antibodies in available randomized clinical trials
Author, Year Phase, setting Participants (n) Follow-up Binding antibodies Neutalizing antibodies Clinical implications
Eptinezumab
Dodick, 2014 [32] II, EM 174 3 months 11/81 – None
Erenumab
Sun, 2016 [44] II, EM 483 3 months 13/107 for 7 mg
12/102 for 21 mg
8/104 for 70 mg
5/107 for 7 mg
3/102 for 21 mg
1/104 for 70 mg
None
Tepper, 2017 [45] II, CM 667 3 months 11/190 for 70 mg
3/188 for 140 mg
0 None
ARISE [36] III, EM 955 6 months 8.0% for 70 mg
3.2% for 140 mg
0.2% for 70 mg
0 for 140 mg
None
STRIVE [34] III, EM 577 3 months 4.3% for 70 mg 0.3% for 70 mg* None
Fremanezumab
Bigal, 2015 [27] IIb, EM 297 3 months 1%§ – None
Bigal, 2015 [26] IIb, CM 264 3 months 1%§ – None
HALO EM [34] III, EM 875 3 months 1.4% for the monthly dosing
0 for single high dose
– None
HALO CM [41] III, CM 1130 3 months 1% – None
Galcanezumab
REGAIN [31] III, CM 836 3 months 2.7% for 120 mg
2.6% for 240 mg
2.3% for 120 mg
1.5% for 240 mg
None
Dodick, 2014 [33] II, EM 218 3 months 15.7%# None
EVOLVE 2 [42] IIb, EM 936 3 months – – None
EVOLVE 1 [43] III, EM 1671 6 months 3.5% for 120 mg¶
5.2% for 240 mg¶
0.2% None
*positive at week 4 for but negative at each subsequent visit; §patients were positive at baseline; #including 6.2% of patients who were positive at baseline; ¶only
treatment emergent antibodies
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Clinical question 6 Should binding and/or neutralizing
antibodies be monitored?
Analysis of evidence
The occurrence of binding or neutralizing antibodies
against the anti-CGRP mAb is reported in Table 20. It is
important to note that some of the patients in the RCTs
were positive for those antibodies before initiation of the
study drug and that there were antibody positive patients
even in those taking placebo.
Clinical guide
Data from individual studies indicate that binding and/
or neutralizing antibodies occur infrequently and may
have a variable course over time. At the moment, the
presence of binding and/or neutralizing antibodies has
not been associated with poor response to treatment or
adverse events. Consequently, there is no evidence
which may support the need of antibodies testing in rou-
tine clinical practice. However, this issue should be fur-
ther studied. In fact, duration of treatment in available
studies is limited in time and it cannot be excluded that
the rate of occurrence of binding and/or neutralizing
antibodies in available clinical studies was too low to es-
tablish firm conclusions about their possible implica-
tions. Pooled data from available RCTs or data from real
life studies may add better evidence and further research
should clarify the role of binding and/or neutralizing
antibodies in patients with poor clinical response and
side effects.
Final recommendations based on experts’ opinions are
reported in Table 19.
Conclusions
CGRP mAbs appear promising drugs for migraine pre-
vention. Real-word data will be very important to sup-
port efficacy and safety of those drugs particularly in the
long-term. Future biomarker research should identify
patients more prone to respond to CGRP mAbs and en-
able clinicians to personalize treatment decisions.
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